The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Šumadia district of Serbia

Nemanja  Borovčanin; Elizabeta Ristanović; Milena Todorović; Milica  Borovčanin; Mirjana Jovanović; Bela Balint

doi:10.2298/VSP170814129B

Nemanja Borovčanin Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia
Elizabeta Ristanović Military Medical Academy, Institute for Microbiology, Belgrade, Serbia
Milena Todorović Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia
Milica Borovčanin University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Mirjana Jovanović University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Bela Balint Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP170814129B

Keywords: opioid-related disorders;, blood-borne pathogens;, methadone;, hepatitis b virus;, hepatitis c virus;, hiv;, serology;, demography;, serbia.

Abstract

Background/Aim. Intravenous drug users (IDUs) are still a high risk-group for cross-reacting blood-borne infections, for vertical pathogen transmission as well as for potentially blood/plasma donation (especially as “paid” donors). The aim of our study was to establish the profile of opiate addict and prevalence of blood-borne pathogens – Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) among 99 patients on substitution therapy with methadone and buprenorphine from Šumadia District. Methods. The Treatment Demand Indicator (TDI) of Pompidou-questionnaire was used to assess the history of drug abuse and risk behavior. All blood samples were tested for HBV surface antigen (HBsAg), anti-HCV antibody (anti-HCV) and HIV antigen/antibody (HIV-Ag/Ab) by Enzyme-Linked ImmunoSorbent Assay (ELISA) or Chemiluminescent Immuno-Assay (CIA). Investigations were also performed for HBV, HCV and HIV by molecular testing – Polymerase Chain Reaction (PCR) method. Results. The majority of patients were males (81.8%), median age 32 (19–57) years, lived in a city (99%), unemployed (58.6%), with finished secondary school (67.7%), unsafe injecting practices (34.3%) and never previously tested for HBV (39.4%), HCV (36.4%) nor HIV (28.3%); only 4% of them previously got HBV-vaccine. The complementary testing resulted with following results: HBV ELISA/CIA and PCR negativity for 66 patients and positive results (by ELISA/CIA and PCR) for 19 patients. However, a difference was observed in the ELISA/CIA-negative/PCR-positive result for 12 and ELISA/CIA-positive/PCR-negative for two patients respectively. Further, the negative results for HCV (ELISA/CIA and PCR testing) were found in 15 IDUs and positive results (using both methods) were found in 58 patients. Different results for ELISA/CIA-negative / PCR-positive results were found in 11 IDUs and ELISA/CIA-positive/PCR – negative results were found in 15 patients. All investigated IDUs were negative for HIV (ELISA/CIA and PCR testing) and for pathogens of opportunistic infection (Cryptococcus neoformans; Pneumocystis carinii; PCR testing), as well as for West Nile Virus (PCR testing). Just one IDU was positive for syphilis (ELISA and confirmatory testing). Conclusion. Our study demonstrated that the positivity for HBV and HCV is still very high (33.4% and 84.8%, respectively) in IDUs. Thus, we suggest that drug users have to be periodically screened using a complementary serological/molecular testing – concerning differences/discrepancies in the results obtained using these methods.

Author Biography

Nemanja Borovčanin, Military Medical Academy, Institute for Transfusiology and Hemobiology, Belgrade, Serbia

Institute of Transfusiology and Hemobiology

References

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9(7): e103345.

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsycho-pharmacol 2011; 21(9): 655–79.

Wales N. A review of viral hepatitis in injecting drug users and assessment of priorities for future activates. Geneva: WHO; 2009.

Gyarmathy VA, Neaigus A, Li N, Ujhelyi E, Caplinskiene I, Caplinskas S, et al. Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human im-munodeficiency virus. Scand J Infect Dis 2011; 43(1): 32–42.

Ruan Y, Liang S, Zhu J, Li X, Pan SW, Liu Q, et al. Evaluation of harm reduction programs on seroincidence of HIV, hepati-tis B and C, and syphilis among intravenous drug users in southwest China. Sex Transm Dis 2013; 40(4): 323–8.

Djukić Dejanović S, Borovčanin M. Principes of treatment of opi-ate dependents in Serbia. In: Djukić Dejanović S, Nastasić P, edi-tors. Dependence diseases: Modern achivements in Preven-tion, treatment and rehabilitation Beograd: ECPD; 2015. p. 10–2. (Serbian)

Тrkuljić M, Borovčanin N, Vučetić D, Jovičić D. Transmissible dis-eases – Etiopathogenesis, markers testing, inactivation of pathogenes. In: Balint B, Trkuljić M, Todorović M, editors. Basic principles of chemotherapy. Beograd: Čigoja štampa; 2010. p. 421–505. (Serbian)

Vučetić D, Kecman G, Ilić V, Balint B. Blood donors' positivity for transfusion-transmissible infections: the Serbian Military Medical Academy experience. Blood Transfus 2015; 13(4): 569–75.

Simon R, Donmall M, Hartnoll R, Kokkevi A, Ouwehand AW, Stauffacher M, et al. The EMCDDA/Pompidou Group treat-ment demand indicator protocol: a European core item set for treatment monitoring and reporting. Eur Addict Res 1999; 5(4): 197–207.

Allain PJ. Emerging Viruses in Transfusion. In: Barbara JA, Regan FA, Contreras MC, editors. Transfusion Microbiology. New York: Cambridge University Press; 2008. p. 75–86.

Honarvar B, Odoomi N, Moghadami M, Kazerooni PA, Has-sanabadi A, Dolatabadi PZ, et al. Blood-Borne Hepatitis in Opiate Users in Iran: A Poor Outlook and Urgent Need to Change Nationwide Screening Policy. PLoS One 2013; 8(12): e82230.

Zamania S, Radfarb R, Nematollahic P, Fadaiec R, Meshkatic M, Mortazavia S, et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 2010; 21(6): 493–500.

Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, et al. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Ann Ist Super Sanità 2010; 46(1): 59–65.

Goulao J, Götz W. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2012: The state of the drug problem in Europe. Lisbon: EMCDDA; 2012.

Amon JJ. Hepatitis in drug users: time for attention, time for action. Lancet 2011; 378 (9791): 543–4.

Balint B, Vucetic D, Todorovic-Balint M, Borovcanin N, Jovanovic-Cupic S, Mandusic V. Safety improving by complementary sero-logical and molecular testing combined with pathogen reduc-tion of the donated blood in window period (Letter). Transfus Apher Sci 2013; 49(1): 103–4.

Busch M, Glynn S, Stramer S, Orland J, Murphy E, Wright D, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV- seropositive blood donors. Transfusion 2006; 46(3): 469–75.

Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfu-sion 2004; 44(9): 1332–9.